reports
Sogefi: 1 director
A director at Sogefi sold 100,000 shares at 3.010EUR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...
- Paul Charpentier
Nexi - Solid start to the year
Nexi reported solid numbers in Q1 2024 with 6.0% revenue growth that was 70bp above expectations. As the consensus already factors in a deceleration in organic growth and a contained increase in profitability for FY2024e, we see limited downside to current expectations. Given that the valuation mul
- Oscar Haffen Lamm
MedinCell: Continues to deliver! We are confident on the safety readou...
Yesterday, Teva and MedinCell announced positive phase 3 efficacy results from its phase 3 trial evaluation mdc-TJK (TEV-'749), a LAI olanzapine, as a once-monthly SC LAI in adults with Schizophrenia. The study met its primary endpoint achieving stat. sig. reductions across all three mdc-TJK doses
Catella AB: 2 directors
Two Directors at Catella AB bought/maiden bought 22,000 shares at between 30.430SEK and 30.500SEK. The significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's director...
South Plains Financial Inc: 2 directors
Two Directors at South Plains Financial Inc sold/bought 80,000 shares at 25.000USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
- Damien Choplain
- Martial Descoutures
Argenx : La montée en puissance des produits se poursuit
>T1 en ligne sur les ventes, en dessous sur l’EBIT - Les ventes T1 progressent de 83% y-o-y et de 6% q-o-q pour atteindre 398 M$ (US 347 M$, Japon 18 M$ et EMEA 31 M$), reflétant le fort besoin médical dans la Myasthénie Gravis, la qualité des produits (i.e. Vyvgart et Vyvgart Hytrulo), ainsi que l’excellente exécution du déploiement commercial. Le produit devrait rester sur cette trajectoire de croissance pour atteindre un peak sales estimé à 11 Md$ (vs css 11 Md$) ...
- Anthony Dick
- Michael Foundoukidis
BMW : Decent in relative terms, but that may not be enough
>Q1 slightly below expectations for Autos, 2024 guidance confirmed - BMW reported yesterday morning a set of Q1 2024 results that came in line with expectations overall, but a shade below on the core Autos division (-6% vs css EBIT), see First Take. Whilst volumes were broadly stable over the quarter, the group, like most of its peers, posted lower earnings (EBIT -25% y-o-y, of which -28% for the Automotive division), penalised by falling prices (new and used vehicl...
Form 8.5 (EPT/RI) - Abrdn European Logistics Income Plc
Form 8.5 (EPT/RI) - Abrdn European Logistics Income Plc FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name of exempt principal trader:Investec Bank plc(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeabrdn European Logistics Income plc(c) Name of the party to the offer with which exempt principal trader is...
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinic...
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, announced that it has initiated its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants – see Neur...
Form 8.5 (EPT/RI) - Alpha Financial Markets Consulting Plc
Form 8.5 (EPT/RI) - Alpha Financial Markets Consulting Plc FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name of exempt principal trader:Investec Bank plc(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeAlpha Financial Markets Consulting plc(c) Name of the party to the offer with which exempt principal tra...
e-therapeutics plc shares now trading on JP Jenkins
JP Jenkins Ltd e-therapeutics plc shares now trading on JP Jenkins 09-May-2024 / 07:30 GMT/BST The issuer is solely responsible for the content of this announcement. 9th May 2024 JPJ: ETX ISIN: GB00B2823H99 e-therapeutics plc ("e-therapeutics" or "ETX" or the "Company") Shares now trading on JP Jenkins London, UK, 9th May 2024 – e-therapeutics plc (AIM: ETX), a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announces its shares (“ETX”) () have been admitted to trade on JP Jenkins share dealing plat...
- Trung Nguyen
Lippo Malls Indonesia - Event Flash - Exchange Offer For 2024 Notes; Q...
Yesterday, Lippo Malls Indonesia Retail Trust (LMIRT) launched an exchange offer for the USD 7.25% 2024 notes maturing on June 19th, with an outstanding amount of USD 138.4 mn. The company has offered to exchange each of the USD 1,000 principal of the notes for USD 432 of USD 7.5% 2026 notes and a USD 600 cash payment. The funding will come from a credit facility of up to IDR 1.5 tn. We recommend that holders of the 2024 notes participate in the offer. Considering that it requires 70% of hol...
AutoCanada Inc: 1 director
A director at AutoCanada Inc bought 224,977 shares at 21.000CAD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
- Jerôme Bodin
Ströer SE & Co. KGaA : Q1 driven by favourable momentum at OoH
>Neutral rating reiterated - Yesterday Ströer published Q1 results that were more or less fully in line with our forecasts with EBITDA of € 108.4m vs € 111m anticipated. Organic growth was 9% over the quarter. Q1 was particularly dynamic. The OoH activity posted growth of 17.4%, beating our forecasts and the group's guidance (+15%) illustrating the continued market share gains on this media (and specifically Ströer). The group held a conference call following the publ...
- Delphine Brault
- Quentin Borie
Siemens Energy AG : Le dynamisme de Grid Technologies booste les résul...
>T2 2023/24 : un très bon trimestre, grâce à Grid Technologies - Siemens Energy a publié hier matin des résultats T2 supérieurs aux attentes, principalement grâce à la division Grid Technologies. Les commandes s’établissent à 9.5 Md€, -22% en comparable (dont -76% pour Siemens Gamesa, -21% pour Gas Services, +27% pour Grid Technologies). Le CA atteint 8.3 Md€, +3.7% en comparable (-6% pour GS, +25% pour GT, -4.6% pour Siemens Gamesa). L’EBITA ajusté (avant SI – specia...
News from INVL Technology managed companies: NRD Companies reports sig...
News from INVL Technology managed companies: NRD Companies reports significant growth in 2023 May 9th, 2024 – NRD Companies, a global IT and consulting group of companies specializing in governance, economic digital infrastructure development, and subject matter consultancy services, has released its 2023 annual report, showcasing remarkable growth and strategic achievements. In 2023, NRD Companies maintained its focus on developing dedicated products and solutions for the E-Government, Banking, and Retail sectors, alongside providing subject matter consultancy services tailored to its ...
Nxera Pharma Operational Highlights and Consolidated Results for the F...
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024 Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2024. The full report can be found . Chris Cargill, President and CEO of Nxera, commented: “We entered 2024 with a clear vision to capitalize on a number of strategic opportunities and build on the strong foundations we have created, positioning the business for the next stage of its ...
„INVL Technology“ valdomų įmonių naujienos: „NRD Companies” praneša ap...
„INVL Technology“ valdomų įmonių naujienos: „NRD Companies” praneša apie reikšmingą augimą 2023 metais Gegužės 9 d., 2024 m. „NRD Companies“, Lietuvoje veiklą vykdanti tarptautinė įmonių grupė, kuri specializuojasi viešojo sektoriaus ir skaitmeninės infrastruktūros sprendimų kūrime kartu teikiant strategines konsultacijas, neseniai paskelbė 2023 m. metinę ataskaitą, kurioje demonstruojamas puikus augimas ir strateginiai pasiekimai. 2023 m. „NRD Companies“ toliau fokusavosi į viešajam, bankininkystės ir mažmeninės prekybos sektoriams skirtų IT produktų ir sprendimų kūrimą bei teikė konsult...
- Franc Gregori
- Lala Gregorek
- Philippa Gardner
Trinity Delta Lighthouse: Arecor Therapeutics
Trinity Delta view: A deal with a major insulin device player such as Medtronic is undoubtedly a coup for Arecor, providing the opportunity to develop a closer relationship as well as broadening its existing diabetes franchise. This expanding franchise, centred on AT278 and AT247, now includes this novel implantable insulin-pump device combination with Medtronic (addressing an underserved niche patient population), an earlier co-development deal with TRx Biosciences to develop an oral GLP-1 (Mar...
Travis Perkins: TR1 Notification of Major Share Interest
Travis Perkins (TPK) Travis Perkins: TR1 Notification of Major Share Interest 09-May-2024 / 07:15 GMT/BST TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BK9RKT01 Issuer Name TRAVIS PERKINS PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights; An acquisition or disposal of financial instruments 3. Details of person subject to the notification obligation Name Bank of America Corporation City of registered office (if applicable) Country of registe...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.